1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties

Citations Over TimeTop 1% of 2003 papers

Abstract

Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes. The synthesis and structure-activity relationship of a new DPP-IV inhibitor class, N-substituted-glycyl-2-cyanopyrrolidines, are described as well as the path that led from clinical development compound 1-[2-[5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine (NVP-DPP728, 8c) to its follow-up, 1-[[(3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine (NVP-LAF237, 12j). The pharmacological profile of 12j in obese Zucker fa/fa rats along with pharmacokinetic profile comparison of 8c and 12j in normal cynomolgus monkeys is discussed. The results suggest that 12j is a potent, stable, selective DPP-IV inhibitor possessing excellent oral bioavailability and potent antihyperglycemic activity with potential for once-a-day administration.

Related Papers

• → Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine(1988)341 cited
• → Isolation and Biosynthesis of Preussin B, a Pyrrolidine Alkaloid from Simplicillium lanosoniveum(2014)43 cited
• → Bromobenzofuran-Based Non-peptide Antagonists of Angiotensin II: GR138950, a Potent Antihypertensive Agent with High Oral Bioavailability(1994)41 cited
• → Pharmacokinetics of a Micronized, Poorly Water-Soluble Drug, HO-221, in Experimental Animals.(1993)18 cited
• [The pharmacokinetics of rhein in 12 healthy volunteers after oral administration of rhubarb extract].(2005)